ARCA biopharma (FRA:HQ10) Beginning Cash Position : €33.35 Mil (As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Beginning Cash Position?

ARCA biopharma's Beginning Cash Position for the quarter that ended in Jun. 2024 was €33.35 Mil.

ARCA biopharma's quarterly Beginning Cash Position declined from Dec. 2023 (€35.29 Mil) to Mar. 2024 (€34.44 Mil) and declined from Mar. 2024 (€34.44 Mil) to Jun. 2024 (€33.35 Mil).

ARCA biopharma's annual Beginning Cash Position increased from Dec. 2021 (€43.43 Mil) to Dec. 2022 (€50.37 Mil) but then declined from Dec. 2022 (€50.37 Mil) to Dec. 2023 (€38.92 Mil).

ARCA biopharma Beginning Cash Position Historical Data

The historical data trend for ARCA biopharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Beginning Cash Position Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

5.95

6.87

43.43

50.37

38.92

ARCA biopharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Beginning Cash Position	Get a 7-Day Free Trial															37.71	37.63	35.29	34.44	33.35

ARCA biopharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

ARCA biopharma Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

https://www.arcabio.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines